Advances in management of bone disease in breast cancer

Bone

Volumn 48, Issue 1, 2011, Pages 80-87

  Walkington, L ^a   Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Bisphosphonates; Breast cancer; Metastatic; Neoadjuvant

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; DENOSUMAB; DOXORUBICIN; GOSERELIN; IBANDRONIC ACID; LETROZOLE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; VASCULOTROPIN; VITAMIN D; ZOLEDRONIC ACID;

AMENORRHEA; ANTIANGIOGENIC ACTIVITY; BONE DESTRUCTION; BONE DISEASE; BONE METASTASIS; BONE PAIN; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FLU LIKE SYNDROME; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; NONHUMAN; OSTEOPOROSIS; OVARY INSUFFICIENCY; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POSTMENOPAUSE; PREMENOPAUSE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SPINAL CORD COMPRESSION;

EID: 78650308350     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.05.037     Document Type: Review

References (68)

1. Winter M.C., Coleman R.E. Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr Opin Oncol 2009, 21:499-506.
2. Coleman R.E., Body J.-J., Gralow J.R., Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitor and associated treatment strategies. Cancer Treat Rev 2008, 34:531-542.
3. Clines G.A., Guise T.A. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005, 12:549-583.
4. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
5. American Cancer Society Breast cancer facts and figures 2007-2008 2007, American Cancer Society Inc, Atlanta.
6. Lester J., Dodwell D., McCloskey E., Coleman R. The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 2005, 31:115-142.
7. Holen I., Coleman R.E. Bisphosphonates as treatment of bone metastases. Curr Pharma Design 2010, 16:1262-1271.
8. Wong R., Witten P.J. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002, 2:CD002068.
9. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res Oct 15, 2006, 12(20 suppl).
10. Russell G., Xia Z., Dunford J.E., Oppermann U., et al. Bisphosphonates: an update on mechanism of action and how these relate to clinical efficacy. Ann NY Acad Sci 2007, 117:209-257.
11. Rogers M.J., Gordon S., Benford H.L. Cellular and molecular mechanism of action of bisphosphonates. Cancer 2000, 88(12 suppl):2961-2978.
12. Luckman S.P., Hughes D.E., Coxon F.P., Russell M.G., et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-598.
13. Coxon F.P., Helfrich M.H., Sebti S., Ralston S.H., et al. Protein geranylgeranylation is required for osteoclast formation, function and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000, 15(8):1467-1476.
14. Benford H.L., Mc Gowan N.W., Helfrich M.H., Nuttall M.E., et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in-vitro. Bone 2001, 28(5).
15. Timble J.W., Gelnndig G.A., Schulman K.A. Health-related quality of life among patients with breast cancer receiving zolendronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004, 42(2):164-175.
16. Delea T., Langer C., McKieman J. The cost of treatment of skeletal-related events in patients with bone metastasis from lung cancer. Oncology 2004, 67(50):390-396.
17. Patterson A.H., Powles T.J., Kanis J.A. Double-blind controlled trial of oral clondronate in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11:59-65.
18. Body J.J., Diel I.J., Linchinister M.R., Bell R., et al. IV ibandronate reduces risk of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2005, 14:1399-1405.
19. Body J.J., Diel I.J., Bell R., Pecherstorfer M., et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004, 111:306-312.
20. Kohno N., Aogi K., Minami H., Nakamura S., et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastasis from breast cancer: randomised, placebo-controlled trial. J Clin Oncol 2005, 23:3314-3321.
21. Rosen L.S., Gordon D., Tchekmedyian N.S., Yanagihara R., et al. Long term efficacy and safety of zolendronic acid in treatment of skeletal metastasis in patients with non-small cell lung cancer and other solid tumours: a randomised phase III, double-blinded, placebo-controlled trial. Cancer 2004, 100:2613-2621.
22. Hilner B.E., Ingle J.N., Chlebowski R.T., Gralow R., et al. American Society of Clinical Oncology 2003 update on role of bisphosphonates and bone disease in women with breast cancer. J Clin Oncol 2003, 21(21):4042-4057.
23. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (version 2.2008) http://www.nccn.org.
24. Brown J.E., Cook R.J., Major P., Saad F., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumours. J Natl Cancer Inst 2005, 97:59-69.
25. Brown J.E., Thomson C.S., Ellis S.P., Gutcher S.P., et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003, 89:2031-2037.
26. Coleman R.E., Major P., Lipton A., Brown J.E., et al. Predictive value of bone resorption and formation markers in cancer patients receiving the bisphosphonate zolendronic acid. J Clin Oncol 2005, 23:4925-4935.
27. Lipton A., Cook R.J., Major P., Saad F., et al. Zolendronic acid and survival in breast cancer patients with bone metastasis and elevated markers of osteoclast activity. Oncologist 2007, 12:1035-1043.
28. Coleman R.E. Risks and benefits of bisphosphonates. Br J Cancer 2008.
29. Guarneri V., Donati S., Nicolini M., Giovannelli S., D'Amilo R., Conte P.F. Renal safety and efficacy of intravenous bisphosphonates in patients with skeletal metastases for up to 10years. Oncologist 2005, 10:842-848.
30. Kholsa Burr D., Cauley J., Dempster D.W., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J Bone Miner Res 2007, 22(10):1479-1491.
31. Wilkinson G.S., Kuo Y.-F., Freeman J.L., Goodwin J.S. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a populations-based analysis. J Natl Cancer Inst 2007, 99:1016-1024.
32. Hoff A.O., Toth B.B., Atlundag K., Johnson M.M., et al. Osteonecrosis of the jaw in patients receiving bisphosphonate therapy. J Clin Oncol ASCO Annual Meeting Proceedings Part I 24 June 2006, No 18 S:8528. Supplement.
33. Lipton A., Steger G., Figueroa J., Alvarado C., et al. Randomised active-controlled phase II study of denosumab: efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007, 25(28):4431-4437.
34. Stopeck A, Body JJ, Fujimawara Y. Denosumab demonstrates superiority over zometa(R) in delay of complications due to bone metastases in advanced breast cancer patients ECCO/ESMO 2009 (Abstract 2LBA).
35. Pfeilschiffer J., Diel I.J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000, 18:1570-1593.
36. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., Adams J.E. Effect of an aromatase inhibitor on bone mineral density and bone turnover markers: 2year results of the anastrozole, tamoxifen alone or in combination (ATAC) trial. J Bone Miner Res 2000, 21:1215-1223.
37. Saarto T., Blomqvist C., Valimaki M., Makela P., et al. Clondronate improves BMD in post-menopausal breast cancer patients treated with adjuvant anti-oestrogens. Br J Cancer 1997, 75:602-605.
38. Delmas P.D., Balena R., Confravreux E., Hardouin C., et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blinded, placebo-controlled study. J Clin Oncol 1997, 15:955-962.
39. Hines S.L., Mincey B.A., Sloan J.A., Thomas S.P., et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. JCO 2009, 27(7):1047-1053.
40. Gnant M.F.X., Milneritsan B., Luschin-Bbengratha G., Grampps G., et al. Zolendronic acid prevent CTIBL in pre-menopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828.
41. Gnant MFX, Milneritsan B, Luschin-Bbengratha G, Kainberger F et al. BMD at 5-years after diagnosis in premenopausal patients with endocrine responsive breast cancer, after 3-years of adjuvant endocrine therapy with oserelin and tamoxifen or anastrozole or both in combination with zolendronic acid - new results from ABCSG-12. In: Presented at 30th annual San Antonio breast cancer symposium: Dec 13-17 2007, San Antonio, Texas (Abstract 26).
42. Brufsky A, Bundred N, Coleman R, Lambert-Falls R et al. The effect of zolendronic acid on aromatase inhibitor associated bone loss in post-menopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study - 36-month follow-up. In: Presented at 30th annual San Antonio breast cancer symposium: Dec 13-17, 2007 San Antonio, TX (Abstract 27).
43. Brufsky A., Harker W.G., Beck J.T., Carroll R., et al. Zolendronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25:829-836.
44. DeBoer R., Eidtmann H., Lluch A. The ZO-FAST trial: zolendronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24-month BMD results. Breast Cancer Res Treat 2007, 106(suppl 1):536. abstract 501.
45. Schenk N., Llombart A., Frassoladti A. The E-ZO-FAST trial: zolendronic acid effectively inhibits AIBL in postmenopausal women with early breast cancer receiving adjuvant letrozole. Eur J Cancer 2007, 5:186. abstract 2008.
46. Lester J.E., Gutcher S.A., Ellis S.P., Thorpe R., et al. Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: 1year results from the ARIBON study. J Clin Oncol 2007, 25(suppl):165.
47. Waltman N.L., Twiss J.J., Ott C.D., Goss G.J., et al. Testing an intervention for preventing osteoporosis in post-menopausal breast cancer survivors. J Nurs Schlorash 2003, 35:333-338.
48. Sawka A.M., Ioannidis G., Papaioannou A., Thabane L., et al. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis. J Obstet Gynaecol Can 2005, 27:759-764.
49. Yamada K., Kohno N., Endok K. The role of bisphosphonates and bone health issues in Japanese breast cancer patients: efficacy of alendronate with aromatase inhibitors. J Clin Oncol 2007, 25(suppl):165.
50. Van Poznak C., Hannon R.A., Mackley J.R. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. JCO 2010, 28(6):967-975.
51. Vanachis A., Polyzos N.P., Georgonlias V., Mavroudis D., et al. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis. Gynaecol Oncol Jan 8 2010, Electronic publication ahead of print.
52. Hadji P., Body J.-J., Aapro M.S., Brufsky A., et al. Practical guidance for management of aromatase inhibitor bone loss. Ann Oncol 2008, 19:1407-1416.
53. Reid D.M., Doughty J., Eastell R., Heys S.D., et al. Guidance for the management of breast cancer treatment induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev 2008, 34(suppl 1):513-518.
54. Ellis G.K., Bone H.G., Chlebowski R., Paul D., et al. Randomised trial of denosumab in patients receiving adjuvant AI for non-met BC. JCO 2008, 26(30):4875-4882.
55. Ottewell P.D., Woodward J.K., Lefley D.V., Evans C.A., et al. Anticancer mechanisms of doxorubicin and zolendronic acid in breast cancer tumour growth in bone. Caner Ther 2009, 8(10):2821-2832.
56. Neville-Webbe H.L., Rostami-Hodjegan A., Evans C.A., Coleman R.E., et al. Sequence- and schedule-dependent enhancement of zolendronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005, 113:364-371.
57. Ottewell P.D., Monkkonen H., Jones M., Lefley D.V., et al. Anti-tumour effects of doxorubicin followed by zolendronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008, 100:1167-1178.
58. Winter M.C., Thorpe H.C., Burkinshaw H. The addition of zolendronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct anti-tumour activity in breast cancer. Caner Res 2009, 69(suppl 2):S101.
59. Winter M.C., Cross S.S., Ingram C.E., Coleman R.E., et al. ANZAC: a neoadjuvant biomarker study exploring the anti-tumour activity of the addition of zolendronic acid to chemotherapy in breast cancer. Ann Oncol 2009, 20(suppl 2). abstract 165P.
60. Santini D., Vincenzi B., Galluzzo S., Battistoni F., et al. Repeated intermittent low-dose therapy with zolendronic acid induces early, sustained and long-lasting decrease in peripheral VEGF levels in cancer patients. Clin Cancer Res 2007, 99:322-330.
61. Powles T., Patterson A., McCloskey E., Schein P., et al. Reduction in bone relapse and improved survival with oral clondronate for adjuvant treatment of operable breast cancer. [ISRITN 83688026]. Breast Cancer Res 2006, 8:R13.
62. Diel I.J., Jaschke A., Solomayer E.F., Gollan C., et al. Adjuvant oral clondronate improves the overall survival of primary breast cancer with micro-metastases to the bone marrow: a longterm follow-up. Ann Oncol 2008, 12:2007-2011.
63. Shiozawa Y., Havens A.M., Pienta K.J., Taichman R.S., et al. The bone marrow niche: habitat to haemopoietic and mesenchymal stem cells and unwitting host to molecular parasites. Leukaemia 2008, 22:941-950.
64. Coleman R., Bundred N., De Boer R., Llombarto A., Campbell I., Neven P., et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-Z-FAST. Cancer Res 2009, 69(24):733 s.
65. Mauri D., Valachia A., Polyzos N.P., Tsali L., et al. Does adjuvant bisphosphonate alter the natural course of disease: a meta-analysis. J Natl Compr Canc Netw 2010 Mar, 8(3):279-286.
66. Rosen L.S., Gordon D., Kaminski M., Howell A., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III double-blind comparative trial. Cancer J. 2001 Sept-Oct, 7(5):377-387.
67. Rosen L.S., Gordon D., Kaminski M., Howell A., et al. Long-term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer: a randomised, double-blind, multi-center comparative trial. Cancer 2003 Oct 15, 98(8):1735-1744.
68. Carteni G., Bordonaro R., Giotta F., Lorusso V., et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multi-center clinical trial. Oncologist 2006 Jul-Aug, 11(7):841-848.